Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 31, 2022, Sangui BioTech International, Inc. (the "Company" or "Sangui") was notified by the OTC Markets Group (the "OTC") that the OTC had determined to commence proceedings to delist its common stock (the "Common Stock") from the OTCQB as a result of the Company's failure to comply with the continued listing standard set forth in the OTCQB Standards, Section 2.3(2) which states that the company must "maintain proprietary priced quotations published by a Market Maker in OTC Link with a minimum closing bid price of $.01 per share on at least one of the prior thirty consecutive calendar days."

On November 2, 2022, the Company's Common Stock was automatically moved down to, and was available to immediately trade, on the Pink Market, which is also operated by OTC Markets Group Inc. The Company will continue to be traded under the symbol "SGBI," and the Company intends to remain current in its Security and Exchange Commission public reporting requirements following the transfer to the Pink Market.

© Edgar Online, source Glimpses